Skip to main content

Table 4 Summary of cost and outcome results in the base-case analysis

From: Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy

Strategy Surgery only Adjuvant S-1 Adjuvant XELOX
Cost of relapse-free state 445.8 14,776.3 13,468.3
Cost of disease recurrent state 12,248.6 8,984.7 6,166.6
Cost of death from gastric cancer 1,174.8 1,101.4 1,091.7
Total cost ($) 13,638.2 24,503.1 20,331.6
QALYs 8.1 10.8 11.5
Incremental cost per QALY*   6,837 3,502
  1. Key: “*” compared with Surgery only.